Why DemeRx’s FDA-cleared DMX-1001 IND could matter for alcohol use disorder drug development
Find out how DemeRx’s DMX-1001 IND acceptance could reshape alcohol use disorder drug development and what risks remain.
Clearmind Medicine Inc. and Polyrizon Ltd. target formulation risk in MEAI’s addiction program
Discover how Clearmind Medicine Inc.’s intranasal MEAI strategy could reshape CNS drug delivery and clinical outcomes. Read the analysis.